Thrombin-induced hyperactivity of platelets of young stroke patients: Involvement of thrombin receptors in the subject-dependent variability in Ca2+ signal generation

Thrombosis and Haemostasis

Volumn 88, Issue 6, 2002, Pages 931-937

  Vanschoonbeek, Kristof ^a   Feijge, Marion A H ^a   Keuren, Jeffrey F W ^a   Coenraad Hemker, H ^a   Lodder, Jan J ^b   Hamulyák, Karly ^b   Van Pampus, Elisabeth C M ^b   Heemskerk, Johan W M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aspirin; Calcium; Ischemic stroke; Platelets; Thrombin receptors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIGOUT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LAXATIVE; LOW MOLECULAR WEIGHT HEPARIN; LYSINE ACETYLSALICYLATE; NITRATE; OPIATE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 AGONIST; SEDATIVE AGENT; THROMBIN; THROMBIN RECEPTOR; UNCLASSIFIED DRUG; VITAMIN;

ADULT; ARTERY DISEASE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL ACTIVITY; CELL STIMULATION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; STROKE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 12244260079     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613336     Document Type: Article

References (39)

1. Johnson CJ, Kittner SJ, McCarter RJ, Sloan MA, Stern BJ, Buchholz D, Price TR. Interrater reliability of an etiologic classification of ischaemic stroke. Stroke 1995; 26: 46-51.
2. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf P, Del Zoppo GJ. Primary prevention of ischemic stroke. A statement for healthcare professionals from the stroke council of the American Heart Association. Circulation 2001; 103: 163-82.
3. Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JW. Ischaemic heart disease and platelet aggregation: The Caerphilly Collaborative Heart Disease Study. Circulation 1998; 83: 38-44.
4. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn P.F. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-7.
5. Uchiyama S, Yamazaki M, Maruyama S, Handa M, Ikeda Y, Fukuyama M, Itagaki I. Shear-induced platelet aggregation in cerebral ischaemia. Stroke 1994; 25: 1547-51.
6. Iwamoto T, Kubo H, Takasaki M. Platelet activation in the cerebral circulation in different subtypes of ischaemic stroke and Binswanger's disease. Stroke 1995; 26: 52-6.
7. Konstantopoulos K, Grotta JC, Sills C, Wu KK, Hellums JD. Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb Haemost 1995; 74: 1329-34.
8. Knight CJ, Panesar M, Wright C, Clarke D, Butowski PS, Patel D, Patrineli A, Fox K, Goodall AH. Altered platelet function detected by flow cytometry: Effects of coronary arterial disease and age. Arterioscler Thromb Vasc Biol 1997; 17: 2044-53.
9. Bihour C, Durrieu-Ja's C, Macchi L, Poujol C, Coste P, Besse P, Nurden P, Nurden AT. Expression of markers of platelet activation and the interpatient variation in response to abciximab. Arterioscler Thromb Vasc Biol 1999; 19: 212-9.
10. Del Zoppo GJ. The role of platelets in ischemic stroke. Neurology 1998; 51: S9-14.
11. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
12. Bednar MM, Gross CE. Antiplatelet therapy in acute cerebral ischemia. Stroke 1999; 30: 887-93.
13. Ringelstein EB, Nabavi D. Long-term prevention of ischaemic stroke recurrence. Thromb Res 2000; 98: V83-96.
14. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopedine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7.
15. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348, 1329-39.
16. Reininger CB, Graf J, Reininger AJ, Spannag M, Steckmeier B, Schweiberer L. Increased platelet and coagulatory activity indicate ongoing thrombogenesis in peripheral arterial disease. Thromb Res 1996; 82: 523-32.
17. Heemskerk JWM. Calcium and platelets. In: The Molecular Basis of Calcium Action in Biology and Medicine (Pochet R, Donato R, Haiech J, Heinzmann C, Gerke V, eds), 2000, Kluwer Acad Publ, The Hague, the Netherlands 45-71.
18. 2+-ATPases. Br J Haematol 1998; 102: 850-9.
19. i signalling of platelets from healthy volunteers. Platelets 1998; 9: 179-83.
20. Rao AK, Kowalska MA, Disa J. Impaired cytoplasmic ionized calcium mobilization in inherited platelet secretion defects. Blood 1989: 74: 664-72.
21. Weiss HJ, Lages B. Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity. A comparison with Scott syndrome. Blood 1997; 89: 1599-1611.
22. 2+-mobilizing potency of α-thrombin and thrombin-receptor-activating peptide on human platelets. Eur J Biochem 1997; 249: 547-55.
23. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet-activation in Gαq-deficient mice. Nature 1997; 389: 183-6.
24. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
25. Siljander P, Farndale RW, Feijge MAH, Comfurius P, Kos S, Bevers EM, Heemskerk JWM. Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol 2001; 21: 618-27.
26. Rosing J, Van Rijn JLML, Bevers EM, Van Dieijen G, Comfurius P, Zwaal RFA. The role of activated human platelets in prothrombin and factor X activation. Blood 1985; 65: 319-22.
27. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpainter K. P1A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet 1997; 349: 385-8.
28. Reiner AP, Aramaki KM, Teramura G, Gaur L. Analysis of the platelet glycoprotein Ia allele frequencies in three North American populations reveals genetic associations between nucleotide 870C/T and amino acid 505 Glu/Lys (HPA-5) dimorphisms. Thromb Haemost 1998; 80: 449-56.
29. Vicari AM, Monzani ML, Pellegatta F, Ronchi P, Galli L, Folli F. Platelet calcium homeostasis is abnormal in patients with severe arteriosclerosis. Arterioscler Thromb 1994; 14: 1420-4.
30. Smeets EF, Heemskerk JWM, Comfurius P, Bevers EM, Zwaal RFA. Thapsigargin amplifies the platelet procoagulant response caused by thrombin. Thromb Haemost 1993; 70: 1024-9.
31. 1. Blood 1997; 89: 1235-42.
32. 1. J Biol Chem 1997; 272: 27035-41.
33. A2 polymorphism. Br J Haematol 1997; 99: 801-7.
34. 1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999; 93: 3583-6.
35. Hassan A, Markus HS. Genetics and ischaemic stroke. Brain 2000; 123: 1787-1812.
36. Meiklejohn DJ, Vickers MA, Morrison ER, Dijkhuisen R, Moore I, Urbaniak SJ, Greaves M. In vivo platelet activation in atherothrombotic stroke is not determined by polymorphisms of human platelet glycoprotein IIIa or Ib. Br J Haematol 2001; 112: 621-31.
37. Arnaud E, Nicaud V, Poirier O, Rendu F, Alhenc Gelas M, Fiessinger JN, Emmerich J, Aiach M. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. Arterioscler Thromb Vasc Biol 2000; 20: 585-92.
38. Bates SM, Weitz JI. Prevention of activation of blood coagulation during acute coronary ischemic syndromes: Beyond aspirin and heparin. Cardiovasc Res 1999; 41: 418-32.
39. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-5.